Xcel Wealth Management LLC Has $3.10 Million Stock Position in Abbott Laboratories $ABT

Xcel Wealth Management LLC boosted its stake in shares of Abbott Laboratories (NYSE:ABT) by 55.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 30,182 shares of the healthcare product maker’s stock after purchasing an additional 10,735 shares during the quarter. Xcel Wealth Management LLC’s holdings in Abbott Laboratories were worth $3,099,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. MidAtlantic Capital Management Inc. acquired a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $25,000. Cornerstone Financial Management LLC bought a new position in shares of Abbott Laboratories during the 4th quarter worth approximately $25,000. Purpose Unlimited Inc. acquired a new stake in Abbott Laboratories in the 4th quarter valued at $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in Abbott Laboratories in the fourth quarter valued at $26,000. Finally, Abound Financial LLC acquired a new position in Abbott Laboratories during the fourth quarter worth $26,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Stock Performance

Abbott Laboratories stock opened at $93.12 on Friday. The stock has a 50-day simple moving average of $89.23 and a 200 day simple moving average of $105.46. The stock has a market capitalization of $162.19 billion, a price-to-earnings ratio of 26.08, a P/E/G ratio of 1.56 and a beta of 0.63. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.54.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. During the same quarter last year, the company posted $1.09 EPS. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, research analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.7%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 70.59%.

Insider Activity at Abbott Laboratories

In other news, CFO Philip P. Boudreau acquired 2,200 shares of Abbott Laboratories stock in a transaction on Thursday, April 23rd. The shares were purchased at an average price of $91.50 per share, with a total value of $201,300.00. Following the acquisition, the chief financial officer owned 2,200 shares in the company, valued at $201,300. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Daniel J. Starks acquired 10,000 shares of the firm’s stock in a transaction on Monday, April 27th. The stock was purchased at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the transaction, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders own 0.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ABT. Citigroup lowered their target price on shares of Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Leerink Partners reduced their price target on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a research report on Tuesday, April 21st. Mizuho decreased their price objective on shares of Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating on the stock in a research note on Friday, April 17th. Sanford C. Bernstein dropped their price objective on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Finally, Stifel Nicolaus reduced their target price on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus price target of $118.30.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott announced a global licensing agreement with ALZpath to develop a blood-based Alzheimer’s diagnostic test for its Alinity ci-series systems, opening a potential new growth avenue in high-demand neurology testing. Article: ALZpath signs licensing deal with Abbott to develop Alzheimer’s blood test
• Positive Sentiment: Recent commentary highlighted Abbott’s expanding diabetes franchise, especially FreeStyle Libre, and said the stock looks attractive after sector rotation pushed it lower, with one note calling it a “Buy” on growth and catalyst potential. Article: Buy, Hold, or Sell: Tech Compression Dragged Abbott Labs Under $91, but 1 Massive Diabetes Catalyst Makes It a Screaming Buy
• Positive Sentiment: Multiple articles pointed to strong investor sentiment, including bullish hedge fund positioning and estimates of roughly 31% upside, suggesting Wall Street still views Abbott as a quality large-cap healthcare name. Article: How Does Wall Street View Abbott Laboratories (ABT)’s Outlook?
• Positive Sentiment: Coverage also emphasized Abbott’s dividend record, four-segment business model, and recession-resistant cash flow, which can support the stock during periods of market rotation away from defensive names. Article: 3 Dividend Aristocrat Stocks with 20%+ Upside — June 25, 2026
• Neutral Sentiment: Abbott said it will host its second-quarter earnings conference call on July 16, keeping attention on upcoming results and guidance but not changing fundamentals yet. Article: Abbott hosts conference call for second-quarter earnings
• Neutral Sentiment: Other recent pieces cited emerging-market momentum in established pharmaceuticals and new sensor distribution in Europe, adding to the bullish narrative without being major near-term stock drivers. Article: How Are Emerging Markets Supporting Abbott’s EPD Momentum?

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.